Size-shrinking nanoparticles with high drug-protein payload for efficient, non-invasive treatment of corneal neovascularization
{{output}}
Corneal neovascularization (CNV) is one of the leading causes of corneal blindness, affecting millions of people worldwide. Anti-vascular endothelial growth factor agents, such as Bevacizumab (Beva), offer high specificity and low side effects. However, their ... ...
